JP2024506909A5 - - Google Patents

Info

Publication number
JP2024506909A5
JP2024506909A5 JP2023548686A JP2023548686A JP2024506909A5 JP 2024506909 A5 JP2024506909 A5 JP 2024506909A5 JP 2023548686 A JP2023548686 A JP 2023548686A JP 2023548686 A JP2023548686 A JP 2023548686A JP 2024506909 A5 JP2024506909 A5 JP 2024506909A5
Authority
JP
Japan
Prior art keywords
nitrogen
sulfur
independently selected
oxygen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506909A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/070627 external-priority patent/WO2022174253A1/en
Publication of JP2024506909A publication Critical patent/JP2024506909A/ja
Publication of JP2024506909A5 publication Critical patent/JP2024506909A5/ja
Pending legal-status Critical Current

Links

JP2023548686A 2021-02-12 2022-02-11 Hpk1アンタゴニスト及びその使用 Pending JP2024506909A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148857P 2021-02-12 2021-02-12
US63/148,857 2021-02-12
PCT/US2022/070627 WO2022174253A1 (en) 2021-02-12 2022-02-11 Hpk1 antagonists and uses thereof

Publications (2)

Publication Number Publication Date
JP2024506909A JP2024506909A (ja) 2024-02-15
JP2024506909A5 true JP2024506909A5 (cg-RX-API-DMAC7.html) 2025-02-18

Family

ID=82837982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548686A Pending JP2024506909A (ja) 2021-02-12 2022-02-11 Hpk1アンタゴニスト及びその使用

Country Status (5)

Country Link
US (1) US12252488B2 (cg-RX-API-DMAC7.html)
EP (1) EP4291235A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506909A (cg-RX-API-DMAC7.html)
CN (1) CN117120090A (cg-RX-API-DMAC7.html)
WO (1) WO2022174253A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN116063329A (zh) * 2021-10-29 2023-05-05 北京望实智慧科技有限公司 Hpk1抑制剂、制备方法及其用途
WO2023193759A1 (en) * 2022-04-07 2023-10-12 Insilico Medicine Ip Limited Hpk1 antagonists and uses thereof
GB202216324D0 (en) * 2022-11-02 2022-12-14 Cerevance Ltd Novel compounds
TW202434215A (zh) * 2022-12-26 2024-09-01 香港商英矽智能科技知識產權有限公司 螺環hpk1拮抗劑及其用途
US11932649B1 (en) 2023-08-17 2024-03-19 King Faisal University 5-(3-substituted phenyl)-pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione derivatives as anticancer agents

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2475569A (en) 1944-02-07 1949-07-05 American Cyanamid Co Substituted pyridine compound
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
KR100833371B1 (ko) 2001-04-27 2008-05-28 젠야쿠코교가부시키가이샤 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003211384B2 (en) * 2002-02-21 2008-12-11 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivative and use thereof
MXPA05001766A (es) 2002-08-14 2005-08-19 Atugen Ag Uso de proteina quinasa n beta.
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
US7129260B2 (en) 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
CA2627892A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR101533461B1 (ko) 2006-04-26 2015-07-02 에프. 호프만-라 로슈 아게 Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
JPWO2008047831A1 (ja) 2006-10-17 2010-02-25 協和発酵キリン株式会社 Jak阻害剤
WO2008105515A1 (ja) * 2007-02-28 2008-09-04 Taisho Pharmaceutical Co., Ltd. 新規なヒドロキサム酸誘導体
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
KR20100015857A (ko) * 2007-04-23 2010-02-12 노파르티스 아게 S1p 수용체 조절 활성을 갖는 프탈라진 및 이소퀴놀린 유도체
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
CN102574847A (zh) * 2009-07-30 2012-07-11 Irm责任有限公司 作为syk激酶抑制剂的化合物和组合物
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
EP2516434B1 (en) 2009-12-23 2015-05-27 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012097479A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic inhibitors of anaphastic lymphoma kinase
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
TW201329067A (zh) 2011-12-08 2013-07-16 Amgen Inc 作為gka活化劑之脲化合物
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2014140739A (ru) * 2012-03-09 2016-04-27 Лексикон Фармасьютикалз, Инк. Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
EP2922841B8 (en) 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
US9340540B2 (en) 2014-02-28 2016-05-17 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
RS61919B1 (sr) 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
CN108699077B (zh) 2016-01-15 2021-03-02 英安塔制药有限公司 作为rsv抑制剂的杂环化合物
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CN110678466B (zh) 2017-03-30 2023-01-31 豪夫迈·罗氏有限公司 作为hpk1抑制剂的二氮杂萘类
MX2019010302A (es) 2017-03-30 2019-11-21 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1.
WO2019070742A1 (en) * 2017-10-03 2019-04-11 Sidecar Therapeutics, Inc. APOPTOSIS SIGNAL REGULATION KINASE 1 (ASK 1) INHIBITORS COMPOUNDS
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
CA3103304A1 (en) * 2018-06-15 2019-12-19 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CA3112510A1 (en) 2018-10-29 2020-05-07 Boehringer Ingelheim International Gmbh Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
CN113645964B (zh) * 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于胎记治疗的芳基苯胺和杂芳基苯胺化合物
BR112021009994A2 (pt) * 2018-11-28 2021-08-17 Takeda Pharmaceutical Company Limited composto, e, medicamento
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
WO2021000935A1 (en) * 2019-07-04 2021-01-07 Qilu Regor Therapeutics Inc. Hpk1 inhibitors and uses thereof
US12215105B2 (en) 2019-09-13 2025-02-04 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof

Similar Documents

Publication Publication Date Title
JP2024509192A5 (cg-RX-API-DMAC7.html)
CA2662320C (en) Bcl inhibitors treating platelet excess
RU2560153C2 (ru) Триазолпиридиновые соединения, ингибирующие jak, и способы
TW202045164A (zh) 化合物、組合物及方法
JP2023552827A5 (cg-RX-API-DMAC7.html)
JP2019530677A (ja) Egfr阻害剤の薬学的な塩及びその結晶形、製造方法並びに使用
US9783513B2 (en) STAT3 inhibitors and their anticancer use
CA2731946A1 (en) Flavin derivatives
JP2004509118A5 (cg-RX-API-DMAC7.html)
JP2018090644A (ja) ホスファチジルイノシトール3−キナーゼ阻害剤
JP2019527718A5 (cg-RX-API-DMAC7.html)
JP2024528986A5 (cg-RX-API-DMAC7.html)
RU2007105350A (ru) 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы
US9108953B2 (en) Quinoline derivatives as bromodomain inhibitors
WO2015157122A1 (en) Mertk-specific pyrazolopyrimidine compounds
JP2017522274A (ja) ホスファチジルイノシトール3−キナーゼ阻害剤
TW202126651A (zh) 吡啶酮化合物及使用方法
HK1231476A1 (zh) 磷脂酰肌醇3-激酶抑制剂
TW201627303A (zh) 磷脂醯肌醇3-激酶抑制劑
AU2018386223A1 (en) Small molecule degraders that recruit DCAFT15
JP6262363B2 (ja) ブロモドメイン阻害剤としてのキノリン誘導体
CN109851638B (zh) 取代的二氨基嘧啶化合物
JP2024525693A5 (cg-RX-API-DMAC7.html)
JP2024545787A (ja) 一酸化窒素送達剤としてのジメチルトリプタミン類似体
AU2007253424B2 (en) (2R)-2-[(4-sulfonyl)aminophenyl]propanamides and pharmaceutical compositions containing them